Literature DB >> 17706282

Thrombospondin-1 (TSP-1) and Survivin (S) expression in non-Hogkin's lymphomas.

Semra Paydas1, Melek Ergin, Seyda Erdogan, Gulsah Seydaoglu, Sinan Yavuz, Umut Disel.   

Abstract

Survivin (S) is a member of inhibitor of apoptosis family (IAP) and is expressed in the majority of malignant tumors but undetectable in normal differentiated adult tissues. S is an encouraging target for cancer therapy. TSP-1 is a multifunctional protein regulating cell growth, motility and apoptosis in both physiological and pathological conditions. The role of TSP-1 in cancer progression remains controversial. We aimed to determine the pathogenetic and prognostic role of TSP-1 and S in non-Hodgkin's lymphomas (NHL). S and TSP-1 expressions were looked for in 177 cases with NHL. S was found to be positive in 94 of the cases (53%). TSP-1 was found to be positive in 31 of the cases (17.5%). There was a strong association between S and TSP-1 and also aggressive histology with S and TSP-1. The overall survival (OS) times were longer in cases without S expression than cases with S expression (p=0.0514). Although the OS was shorter in TSP-1 expressing cases as compared with TSP-1 (-) cases, difference was not significant (p=0.2428). In conclusion, S and TSP-1 expressions were detected in 53 and 17.5% of the cases with NHL, and are associated with aggressive histology and shorter OS.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17706282     DOI: 10.1016/j.leukres.2007.06.024

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  6 in total

1.  Interferon Regulatory Factor 1 (IRF-1) induces p21(WAF1/CIP1) dependent cell cycle arrest and p21(WAF1/CIP1) independent modulation of survivin in cancer cells.

Authors:  Michaele J Armstrong; Michael T Stang; Ye Liu; Jinbo Gao; Baoguo Ren; Brian S Zuckerbraun; Raja S Mahidhara; Quanhua Xing; Eva Pizzoferrato; John H Yim
Journal:  Cancer Lett       Date:  2011-12-23       Impact factor: 8.679

2.  Prognostic value of survivin in patients with non-Hodgkin's lymphoma: a meta-analysis.

Authors:  Chuan He; Zhigang Liu; Jie Ji; Huanling Zhu
Journal:  Int J Clin Exp Med       Date:  2015-04-15

3.  Thrombospondin-1 promotes tumor progression in cutaneous T-cell lymphoma via CD47.

Authors:  Hiroaki Kamijo; Tomomitsu Miyagaki; Naomi Takahashi-Shishido; Rina Nakajima; Tomonori Oka; Hiraku Suga; Makoto Sugaya; Shinichi Sato
Journal:  Leukemia       Date:  2019-11-11       Impact factor: 11.528

Review 4.  Regulation of nitric oxide signalling by thrombospondin 1: implications for anti-angiogenic therapies.

Authors:  Jeff S Isenberg; Gema Martin-Manso; Justin B Maxhimer; David D Roberts
Journal:  Nat Rev Cancer       Date:  2009-02-05       Impact factor: 60.716

5.  Survivin expression in patients with newly diagnosed nodal diffuse large B cell lymphoma (DLBCL).

Authors:  O Markovic; D Marisavljevic; V Cemerikic-Martinovic; T Martinovic; B Filipovic; D Stanisavljevic; R Zivković; J Hajder; N Stanisavljevic; B Mihaljevic
Journal:  Med Oncol       Date:  2012-04-13       Impact factor: 3.064

Review 6.  Molecular pathogenic pathways in extranodal NK/T cell lymphoma.

Authors:  Sanjay de Mel; Susan Swee-Shan Hue; Anand D Jeyasekharan; Wee-Joo Chng; Siok-Bian Ng
Journal:  J Hematol Oncol       Date:  2019-04-02       Impact factor: 17.388

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.